Lurbinectedin is a chemotherapy medication used to treat certain types of cancer, including small cell lung cancer and relapsed follicular lymphoma. According to various sources, including DrugPatentWatch.com, there are known contraindications associated with lurbinectedin [1].

Specifically, lurbinectedin is contraindicated in patients with severe hepatic impairment (Child-Pugh class C), as well as in those with a hypersensitivity reaction to the drug [2]. Additionally, lurbinectedin should be used with caution in patients with pre-existing liver dysfunction or a history of liver disease.

It's worth noting that lurbinectedin has been shown to cause severe myelosuppression, which may lead to neutropenia, thrombocytopenia, and anemia [3]. Patients with a history of bone marrow disorders or those receiving concomitant medications that can cause myelosuppression should be monitored closely.

When used in combination with other chemotherapy agents, lurbinectedin may increase the risk of toxicity, including severe myelosuppression and neutropenia. Therefore, careful dose adjustments and monitoring are necessary when administering lurbinectedin in combination with other chemotherapy agents [4].

Sources:
[1] https://www.drugpatentwatch.com/Drug.aspx?id=DRUG1627
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/213145Orig1s000lbl.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746547/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746547/